Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (111-120 of 387) with videos related to

Pageof 39
Sort By:
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Hematological Oncology|October 25, 2023
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approachKang Le, Jordan Vollenweider, JingJing Han, et al.
Cancer|May 26, 2004
High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosisIrene M Ghobrial, Francis Buadi, Robert J Spinner, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaEmilian Racila, Brian K Link, Wen-Kai Weng, et al.
International Journal of Cardiology|October 16, 2018
Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomesJae Yoon Park, Wei Guo, Mohammed Al-Hijji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar, S Vincent Rajkumar, Robert A Kyle, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Rituximab for IgG4-related disease: a prospective, open-label trialMollie N Carruthers, Mark D Topazian, Arezou Khosroshahi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopyThomas E Witzig, Blaise Bossy, Teresa Kimlinger, et al.
American Journal of Hematology|April 7, 2017
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphomaMoritz Binder, Megan M O'Byrne, Matthew J Maurer, et al.
Pageof 39

Showing results (111-120 of 387) with videos related to

Sort By:
Pageof 39
American Journal of Hematology|April 10, 2014
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom MacroglobulinemiaIrene M Ghobrial, Thomas E Witzig, Morie Gertz, et al.
Hematological Oncology|October 25, 2023
Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approachKang Le, Jordan Vollenweider, JingJing Han, et al.
Cancer|May 26, 2004
High-dose intravenous methotrexate followed by autologous stem cell transplantation as a potentially effective therapy for neurolymphomatosisIrene M Ghobrial, Francis Buadi, Robert J Spinner, et al.
British Journal of Haematology|November 20, 2002
Bone marrow angiogenesis in multiple myeloma: effect of therapyShaji Kumar, Rafael Fonseca, Angela Dispenzieri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2008
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaEmilian Racila, Brian K Link, Wen-Kai Weng, et al.
International Journal of Cardiology|October 16, 2018
Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomesJae Yoon Park, Wei Guo, Mohammed Al-Hijji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar, S Vincent Rajkumar, Robert A Kyle, et al.
Annals of the Rheumatic Diseases|February 11, 2015
Rituximab for IgG4-related disease: a prospective, open-label trialMollie N Carruthers, Mark D Topazian, Arezou Khosroshahi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopyThomas E Witzig, Blaise Bossy, Teresa Kimlinger, et al.
American Journal of Hematology|April 7, 2017
Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphomaMoritz Binder, Megan M O'Byrne, Matthew J Maurer, et al.
Pageof 39